Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHBY)
:RHHBY
RHHBY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$34.10 - $44.31
Previous CloseN/A
Volume3.10M
Average Volume (3M)1.26M
Market Cap
$254.86B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)22.7
Beta0.40
Next Earnings
Jan 29, 2026EPS Estimate
1.43Last Dividend Ex-Date
Mar 28, 2025Dividend Yield3.5%
Share Statistics
EPS (TTM)1.74
Shares Outstanding5,620,501,500
10 Day Avg. Volume1,416,999
30 Day Avg. Volume1,259,298
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$44.00Price Target Upside13.08% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHHBY FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $34.10 and its highest was $44.31 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $254.86B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 29, 2026 which is in 180 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 24, 2025. The company reported $1.742 earnings per share for the quarter, beating the consensus estimate of $1.689 by $0.053.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $1.363 which represents an annual dividend yield of 3.5%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 1.43.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 5,620,501,500 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $1.742 in its last earnings report, beating expectations of $1.689. Following the earnings report the stock price went up 0.729%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHBY
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$44.00 (13.08% Upside)
$44.00 (13.08% Upside)
Blogger Sentiment
Bullish
RHHBY Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 11.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.96%
12-Months-Change
Fundamentals
Return on Equity
31.98%
Trailing 12-Months
Asset Growth
11.69%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG is a global healthcare company headquartered in Basel, Switzerland. It operates in two main sectors: Pharmaceuticals and Diagnostics. The Pharmaceuticals division is focused on the development and distribution of prescription medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The Diagnostics division provides a wide range of products and services, including in vitro diagnostics and tissue-based cancer diagnostics, as well as laboratory, molecular, and point-of-care diagnostics solutions.
RHHBY Company Deck
RHHBY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth in Pharmaceuticals, successful product approvals, and robust pipeline expansion. However, the flat performance in Diagnostics due to China reforms, mixed clinical trial results, and ongoing geopolitical and currency risks were significant concerns. Despite these challenges, the overall performance and strategic advancements suggest a positive outlook.Read More>RHHBY Stock 12 Month Forecast
Average Price Target
$44.00
▲(13.08%Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.61% Mutual Funds
<0.01% Other Institutional Investors
99.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---